Irritable Bowel Syndrome Treatment Market Size & Growth

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Irritable Bowel Syndrome Treatment Market Size Analysis

Global Irritable Bowel Syndrome Treatment Market Introduction
By Product
1. Introduction
  1. Product By Value
2. Rifaximin
  1. By Value
3. Eluxadoline
  1. By Value
4. Lubiprostone
  1. By Value
5. Linaclotide
  1. By Value
6. Others
  1. By Value
By Type
1. Introduction
  1. Type By Value
2. IBS with Diarrhea (IBS-D)
  1. By Value
3. IBS with Constipation (IBS-C)
  1. By Value
4. Mixed IBS
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospitals pharmacies
  1. By Value
3. Drug Stores and Retail Pharmacies
  1. By Value
4. Online pharmacies
  1. By Value

North America Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Rifaximin
  1. By Value
3. Eluxadoline
  1. By Value
4. Lubiprostone
  1. By Value
5. Linaclotide
  1. By Value
6. Others
  1. By Value
By Type
1. Introduction
  1. Type By Value
2. IBS with Diarrhea (IBS-D)
  1. By Value
3. IBS with Constipation (IBS-C)
  1. By Value
4. Mixed IBS
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospitals pharmacies
  1. By Value
3. Drug Stores and Retail Pharmacies
  1. By Value
4. Online pharmacies
  1. By Value
U.S.
1. By Product
  1. Introduction
    1. Product By Value
  2. Rifaximin
    1. By Value
  3. Eluxadoline
    1. By Value
  4. Lubiprostone
    1. By Value
  5. Linaclotide
    1. By Value
  6. Others
    1. By Value
2. By Type
  1. Introduction
    1. Type By Value
  2. IBS with Diarrhea (IBS-D)
    1. By Value
  3. IBS with Constipation (IBS-C)
    1. By Value
  4. Mixed IBS
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospitals pharmacies
    1. By Value
  3. Drug Stores and Retail Pharmacies
    1. By Value
  4. Online pharmacies
    1. By Value
Canada

Europe Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Rifaximin
  1. By Value
3. Eluxadoline
  1. By Value
4. Lubiprostone
  1. By Value
5. Linaclotide
  1. By Value
6. Others
  1. By Value
By Type
1. Introduction
  1. Type By Value
2. IBS with Diarrhea (IBS-D)
  1. By Value
3. IBS with Constipation (IBS-C)
  1. By Value
4. Mixed IBS
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospitals pharmacies
  1. By Value
3. Drug Stores and Retail Pharmacies
  1. By Value
4. Online pharmacies
  1. By Value
U.K.
1. By Product
  1. Introduction
    1. Product By Value
  2. Rifaximin
    1. By Value
  3. Eluxadoline
    1. By Value
  4. Lubiprostone
    1. By Value
  5. Linaclotide
    1. By Value
  6. Others
    1. By Value
2. By Type
  1. Introduction
    1. Type By Value
  2. IBS with Diarrhea (IBS-D)
    1. By Value
  3. IBS with Constipation (IBS-C)
    1. By Value
  4. Mixed IBS
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospitals pharmacies
    1. By Value
  3. Drug Stores and Retail Pharmacies
    1. By Value
  4. Online pharmacies
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Rifaximin
  1. By Value
3. Eluxadoline
  1. By Value
4. Lubiprostone
  1. By Value
5. Linaclotide
  1. By Value
6. Others
  1. By Value
By Type
1. Introduction
  1. Type By Value
2. IBS with Diarrhea (IBS-D)
  1. By Value
3. IBS with Constipation (IBS-C)
  1. By Value
4. Mixed IBS
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospitals pharmacies
  1. By Value
3. Drug Stores and Retail Pharmacies
  1. By Value
4. Online pharmacies
  1. By Value
China
1. By Product
  1. Introduction
    1. Product By Value
  2. Rifaximin
    1. By Value
  3. Eluxadoline
    1. By Value
  4. Lubiprostone
    1. By Value
  5. Linaclotide
    1. By Value
  6. Others
    1. By Value
2. By Type
  1. Introduction
    1. Type By Value
  2. IBS with Diarrhea (IBS-D)
    1. By Value
  3. IBS with Constipation (IBS-C)
    1. By Value
  4. Mixed IBS
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospitals pharmacies
    1. By Value
  3. Drug Stores and Retail Pharmacies
    1. By Value
  4. Online pharmacies
    1. By Value
Korea
Japan
India
Australia
Singapore
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Rifaximin
  1. By Value
3. Eluxadoline
  1. By Value
4. Lubiprostone
  1. By Value
5. Linaclotide
  1. By Value
6. Others
  1. By Value
By Type
1. Introduction
  1. Type By Value
2. IBS with Diarrhea (IBS-D)
  1. By Value
3. IBS with Constipation (IBS-C)
  1. By Value
4. Mixed IBS
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospitals pharmacies
  1. By Value
3. Drug Stores and Retail Pharmacies
  1. By Value
4. Online pharmacies
  1. By Value
UAE
1. By Product
  1. Introduction
    1. Product By Value
  2. Rifaximin
    1. By Value
  3. Eluxadoline
    1. By Value
  4. Lubiprostone
    1. By Value
  5. Linaclotide
    1. By Value
  6. Others
    1. By Value
2. By Type
  1. Introduction
    1. Type By Value
  2. IBS with Diarrhea (IBS-D)
    1. By Value
  3. IBS with Constipation (IBS-C)
    1. By Value
  4. Mixed IBS
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospitals pharmacies
    1. By Value
  3. Drug Stores and Retail Pharmacies
    1. By Value
  4. Online pharmacies
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Rifaximin
  1. By Value
3. Eluxadoline
  1. By Value
4. Lubiprostone
  1. By Value
5. Linaclotide
  1. By Value
6. Others
  1. By Value
By Type
1. Introduction
  1. Type By Value
2. IBS with Diarrhea (IBS-D)
  1. By Value
3. IBS with Constipation (IBS-C)
  1. By Value
4. Mixed IBS
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospitals pharmacies
  1. By Value
3. Drug Stores and Retail Pharmacies
  1. By Value
4. Online pharmacies
  1. By Value
Brazil
1. By Product
  1. Introduction
    1. Product By Value
  2. Rifaximin
    1. By Value
  3. Eluxadoline
    1. By Value
  4. Lubiprostone
    1. By Value
  5. Linaclotide
    1. By Value
  6. Others
    1. By Value
2. By Type
  1. Introduction
    1. Type By Value
  2. IBS with Diarrhea (IBS-D)
    1. By Value
  3. IBS with Constipation (IBS-C)
    1. By Value
  4. Mixed IBS
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospitals pharmacies
    1. By Value
  3. Drug Stores and Retail Pharmacies
    1. By Value
  4. Online pharmacies
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Irritable Bowel Syndrome Treatment Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Abbott
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Synergy Pharma
Mallinckrodt
Bausch Health Companies Inc.
Ardelyx
Astellas Pharma Inc.
Novartis AG, GSK plc.
Ironwood Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment